Skip to content
    Font Size

    Prostate Cancer Drug Zytiga May Extend Life

    Study Shows Zytiga Adds 4 Months of Life to Patients With Advanced Prostate Cancer
    WebMD Health News
    Reviewed by Laura J. Martin, MD

    May 25, 2011 -- The newly approved prostate cancer pill Zytiga (abiraterone acetate) may extend life by up to four months in men with spreading cancer who have already been treated with chemotherapy, a study shows.

    This survival gain "means quite a bit," says study researcher Howard I. Scher, MD, chief of the genitourinary oncology service at Memorial Sloan-Kettering Cancer Center in New York City. "These are a group of patients for whom there is no standard of care and it is particularly gratifying to see these results, to say the least."

    The new study is published in the New England Journal of Medicine.

    Prostate cancer is the most common cancer diagnosed in men besides skin cancer, according to the American Cancer Society. One out of every six men will be diagnosed with prostate cancer during his lifetime.

    The new drug, which was approved by the FDA in April, inhibits a protein that helps form male hormones. The findings may help reshape the way doctors view and treat advanced prostate cancer.

    The new study included 1,195 men with metastatic prostate cancer whose disease had progressed after chemotherapy. Those men who received steroid therapy along with the new pill survived for 14.8 months, on average, compared with 10.9 months seen among those who received a placebo along with steroids. This translated into a 34% reduction in risk of dying, the study shows.

    This survival edge was considered so significant that men who received the placebo were permitted to switch to the new drug before the study was completed.

    Men who took the new pill also saw greater responses in levels of prostate-specific antigen (PSA) than men who received placebo. Elevated levels of PSA may be a marker for prostate cancer.

    The men who took Zytiga also showed improvements in disease-related symptoms and prostate cancer progression on imaging tests compared with men who received the placebo.

    Zytiga side effects included fluid retention, high blood pressure, and a drop in blood potassium levels.

    Drug May Have Wider Role in Treatment

    This group of patients is likely the tip of the iceberg as far as the role that the new drug can play in prostate cancer treatment, Scher says.

    1 | 2 | 3

    Today on WebMD

    man with doctor
    Symptoms, risks, treatments
    man coughing
    Men shouldn’t ignore
    prostate cancer cells
    What does this diagnosis mean?
    doctor and male patient
    Is it worth it?
    cancer fighting foods
    15 Cancer Symptoms Men Ignore
    Prostate Enlarged
    Picture Of The Prostate
    Prostate Cancer Quiz
    screening tests for men
    Prostate Cancer Symptoms
    Vitamin D